respiratori
syncyti
viru
rsv
import
caus
respiratori
tract
diseas
infant
elderli
current
licens
vaccin
rsv
avail
describ
develop
safe
effect
intranas
subunit
vaccin
base
recombin
fusion
f
protein
bound
surfac
immunostimulatori
bacteriumlik
particl
blp
deriv
foodgrad
bacterium
lactococcu
lacti
differ
variant
f
analyz
respect
conform
reactiv
neutral
antibodi
assum
f
protein
mimick
metast
prefus
form
rsv
f
expos
extens
relev
epitop
repertoir
f
protein
correspond
postfus
structur
result
indic
recombin
solubl
ectodomain
rsv
f
readili
adopt
postfus
conform
gener
prevent
ctermin
addit
trimer
motif
whose
format
prevent
mutat
two
furin
cleavag
site
f
put
postfus
form
f
recogn
well
monoclon
antibodi
palivizumab
much
less
potent
neutral
prefusionspecif
antibodi
addit
trimer
motif
mutat
furin
cleavag
site
increas
reactiv
f
highest
reactiv
observ
f
protein
featur
combin
intranas
vaccin
mice
cotton
rat
blp
load
latter
prefusionlik
f
protein
blpf
result
potent
induct
fspecif
immunoglobulin
significantli
decreas
viru
titer
lung
upon
rsv
challeng
moreov
contrast
anim
vaccin
formalininactiv
rsv
anim
receiv
blpf
exhibit
high
level
fspecif
secretori
iga
nose
rsvneutral
antibodi
sera
show
symptom
enhanc
diseas
challeng
rsv
human
respiratori
syncyti
viru
rsv
caus
acut
upper
lower
respiratori
tract
infect
major
caus
hospit
infant
first
year
life
furthermor
reinfect
occur
frequent
steril
immun
never
firmli
establish
rsv
also
caus
signific
diseas
burden
mortal
elderli
compar
influenza
current
avail
option
prevent
rsvmediat
diseas
passiv
administr
commerci
avail
rsvneutral
monoclon
antibodi
mab
palivizumab
howev
use
restrict
infant
consid
high
risk
develop
sever
respiratori
diseas
due
high
cost
although
need
vaccin
protect
specif
risk
group
popul
larg
current
licens
vaccin
rsv
avail
recent
review
rsv
see
rsv
vaccin
develop
hamper
disastr
result
obtain
formalininactiv
fi
viru
vaccin
test
review
diseas
sever
hospit
admiss
rate
increas
vaccin
children
natur
infect
rsv
post
vaccin
sever
death
occur
mechan
vaccineinduc
diseas
enhanc
remain
incomplet
understood
appear
associ
immun
respons
high
level
nonneutr
antibodi
absenc
low
level
neutral
antibodi
recruit
eosinophil
lung
epithelia
nevertheless
larg
number
rsv
vaccin
strategi
explor
vari
success
includ
liveattenu
rsv
strain
subunit
vaccin
viral
vector
vaccin
obvious
success
rsv
vaccin
induc
protect
immun
immunopatholog
rsv
envelop
negativestrand
rna
viru
belong
famili
paramyxovirida
envelop
contain
two
major
glycoprotein
main
target
neutral
antibodi
attach
protein
g
fusion
protein
f
review
two
rsv
antigen
group
b
differ
g
f
protein
f
protein
appear
effici
neutral
protect
antigen
compar
g
may
relat
among
other
high
carbohydr
content
g
protein
may
shield
protein
immun
recognit
addit
g
protein
also
secret
infect
cell
form
may
function
antigen
decoy
f
protein
function
fuse
viral
host
membran
also
play
major
role
viruscel
attach
neutral
antibodi
target
f
may
therefor
interfer
viruscel
attach
andor
viruscel
fusion
rsv
neutral
mab
palivizumab
use
prophylaxi
rsv
infect
recogn
highli
conserv
epitop
f
protein
rsv
f
protein
type
membran
protein
synthes
inact
precursor
protein
assembl
trimer
review
precursor
protein
cleav
furinlik
proteas
transport
secretori
rout
homotrim
coval
link
via
disulfid
bridg
form
metast
prefus
structur
part
contain
heptad
repeat
b
hra
hrb
fusion
peptid
transmembran
domain
latter
two
posit
opposit
side
molecul
upon
viruscel
attach
conform
chang
rsv
f
protein
lead
insert
hydrophob
fusion
peptid
host
cell
membran
fusion
intermedi
refold
highli
stabl
postfus
structur
assembl
postfus
structur
dictat
format
sixhelix
bundl
contain
hra
hrb
region
monom
antiparallel
orient
result
transmembran
domain
locat
downstream
hrb
fusion
peptid
locat
upstream
hra
posit
adjac
posit
consist
fusion
viral
host
membran
achiev
structur
f
protein
postfus
conform
recent
elucid
immuneenhanc
properti
adjuv
normal
use
overcom
low
immunogen
recombin
protein
vaccin
current
studi
howev
made
use
innov
immunostimulatori
carrier
consist
peptidoglycan
sphere
produc
foodgrad
bacterium
lactococcu
lacti
bacterium
kill
low
ph
high
temperatur
gener
bacteriumlik
particl
blp
nonliv
depriv
intact
surfac
protein
intracellular
content
blp
activ
antigen
present
cell
innat
immun
system
tolllik
receptor
interact
shown
act
potent
immunostimul
intranas
immun
blp
admix
vaccin
antigen
may
also
load
antigen
genet
fuse
peptidoglycan
bind
moieti
thu
blp
carri
malaria
parasit
yersinia
pesti
pneumococc
antigen
bound
blp
shown
induc
robust
protect
immun
respons
mous
model
use
blp
technolog
aim
develop
needlefre
mucos
vaccin
protect
rsv
use
f
protein
antigen
choic
end
express
recombin
solubl
variant
f
protein
fuse
peptidoglycan
bind
moieti
subsequ
load
onto
blp
blpf
differ
variant
f
analyz
respect
conform
reactiv
neutral
antibodi
assum
f
protein
mimick
metast
prefus
form
rsv
f
expos
extens
relev
epitop
repertoir
f
protein
correspond
stabl
inact
postfus
structur
agreement
assumpt
magro
cowork
recent
show
antibodi
specif
prefus
form
f
account
neutral
activ
found
human
sera
result
indic
intranas
vaccin
mice
cotton
rat
blp
display
f
protein
expos
prefusionspecif
epitop
induc
strong
fspecif
igg
respons
sera
potent
rsv
neutral
capac
furthermor
vaccin
result
substanti
secretori
iga
siga
level
nose
viru
titer
lung
significantli
decreas
challeng
compar
mockvaccin
anim
contrast
anim
receiv
firsv
sign
vaccinationinduc
enhanc
diseas
symptom
could
observ
upon
rsv
challeng
intranas
vaccin
blpf
prepar
anim
experi
studi
protocol
either
approv
committe
anim
experiment
univers
groningen
netherland
sigmovir
institut
anim
care
util
committe
studi
carri
strict
accord
guidelin
provid
dutch
anim
protect
act
nation
institut
health
respect
effort
made
minim
suffer
two
variant
cdna
clone
correspond
residu
f
protein
european
isol
rsv
serotyp
genbank
access
number
synthes
use
humanpref
codon
genscript
usa
inc
one
cdna
clone
encod
wildtyp
f
protein
ectodomain
clone
encod
f
protein
ectodomain
arginin
residu
two
multibas
furin
cleavag
site
mutat
lysin
rarr
kakk
kkrkrr
kkkkkk
cdna
clone
express
vector
effici
express
mammalian
cell
vector
modifi
f
proteinencod
sequenc
clone
frame
downstream
dna
sequenc
code
signal
peptid
indic
upstream
sequenc
encod
artifici
isoleucin
zipper
trimer
motif
tag
see
fig
tag
either
consist
tripl
streptagii
iba
germani
lysm
peptidoglycan
bind
domain
lysm
domain
follow
tripl
streptagii
schemat
represent
differ
express
construct
see
fig
sequenc
motif
tag
use
provid
fig
codonoptim
dna
fragment
encod
variabl
heavi
light
chain
antibodi
synthes
genscript
usa
inc
clone
infram
pcagg
mammalian
express
vector
contain
human
heavi
light
constant
domain
respect
express
vector
contain
rsv
f
ectodomainencod
sequenc
transfect
cell
use
polyethyleneimin
pei
ww
ratio
dnapei
h
post
transfect
transfect
mixtur
replac
sfmii
express
medium
invitrogen
supplement
sodium
bicarbon
gliter
glucos
gliter
primaton
rluf
gliter
penicillin
unitsml
streptomycin
mgml
glutamax
gibco
dimethyl
sulfoxid
tissu
cultur
supernat
harvest
day
post
transfect
f
protein
either
purifi
use
streptactin
sepharos
bead
accord
manufactur
instruct
iba
germani
analysi
protein
bound
blp
describ
concentr
streptactin
purifi
protein
determin
use
nanodrop
spectrophotomet
isogen
life
scienc
accord
manufactur
instruct
express
vector
encod
heavi
light
chain
cotransfect
ratio
cell
similarli
describ
antibodi
secret
cell
cultur
supernat
bound
protein
sepharos
bead
ge
healthcar
elut
use
citric
acid
ph
eluat
immedi
neutral
use
trishcl
ph
express
secret
recombin
protein
confirm
sodium
dodecylsulf
sd
polyacrylamid
pa
gel
electrophoresi
sdspage
nupag
bistri
invitrogen
follow
western
blot
use
antistreptag
antibodi
conjug
hors
radish
peroxidas
hrp
strepmabclassichrp
iba
palivizumab
synagi
abbott
laboratori
follow
hrpconjug
antihuman
igg
antibodi
itk
southern
biotech
latter
antibodi
also
use
confirm
express
recombin
antibodi
prior
sdspage
analysi
sampl
resuspend
laemmli
sampl
buffer
lsb
either
contain
sigma
heat
minut
indic
purifi
f
protein
mg
mock
treat
vari
amount
tpck
treat
trypsin
mg
rang
per
ml
reaction
volum
bovin
pancrea
sigma
min
subsequ
sampl
put
ice
trypsin
inhibitor
sigma
ad
analyz
sdspage
describ
protein
band
visual
use
colloid
blue
stain
kit
invitrogen
enzymelink
immunosorb
assay
elisa
analysi
recombin
solubl
f
nunc
maxisorp
plate
coat
differ
f
protein
prepar
ngwell
block
phosphat
buffer
salin
pb
vv
bovin
serum
albumin
wv
extens
wash
pb
vv
plate
incub
limit
dilut
palivizumab
start
dilut
mgml
stock
start
dilut
mgml
stock
start
dilut
mgml
stock
extens
wash
plate
incub
hrp
conjug
goatantihuman
igg
antibodi
itk
southern
biotech
dilut
one
hour
room
temperatur
detect
hrp
reactiv
perform
use
tetramethylbenzidin
substrat
biofx
elisa
plate
reader
biotek
experi
repeat
time
result
repres
experi
shown
blp
previous
term
gem
particl
prepar
describ
earlier
brief
cell
overnight
cultur
l
lacti
strain
harvest
wash
steril
distil
water
cell
resuspend
trichloroacet
acid
place
hot
water
bath
min
acid
heat
treatment
kill
bacteria
gener
socal
blp
acid
heat
treatment
blp
pellet
wash
three
time
pbsand
final
resuspend
pb
store
one
mg
blp
defin
approxim
nonliv
particl
prepar
blpbase
vaccin
also
describ
detail
elsewher
short
cultur
supernat
contain
fusion
recombin
protein
concentr
vivaspin
vivaproduct
bind
antigen
achiev
mix
concentr
blp
particl
gentl
agit
min
room
temperatur
follow
extens
wash
pb
remov
unbound
protein
amount
f
protein
bound
blp
determin
compar
colloid
blue
stain
invitrogen
f
protein
sdspa
gel
rel
bovin
serum
albumin
bsa
protein
standard
blp
carri
flysgcn
protein
blpf
analyz
immunofluoresc
microscopi
use
palivizumab
fitclabel
goatantihuman
secondari
antibodi
southern
biotech
usa
prior
anim
experi
blpf
vaccin
prepar
assembl
analyz
store
singl
use
aliquot
balbc
mice
week
purchas
harlan
zeist
netherland
divid
group
n
per
group
anim
immun
prime
vaccin
day
booster
vaccin
day
second
booster
day
group
vaccin
intranas
either
mg
flysgcn
c
termin
lysm
domain
bound
mg
blp
ml
per
dose
ug
similar
f
protein
flysgcn
c
termin
lysm
domain
tag
absenc
blp
respect
group
receiv
formaldehyd
inactiv
rsv
firsv
dilut
ml
per
dose
prepar
accord
calf
muscl
equal
divid
inject
site
week
second
booster
vaccin
blood
sampl
drawn
orbit
punctur
sera
obtain
centrifug
blood
min
sampl
subsequ
store
analysi
nasal
wash
obtain
flush
nasopharynx
ml
pb
proteas
inhibitor
roch
diagnost
lavag
fluid
centrifug
remov
cell
store
use
prototyp
long
strain
rsv
atcc
manassa
va
propag
cell
serial
plaquepurif
reduc
defectiveinterf
particl
pool
viru
design
rsvalong
sucros
stabil
media
sigmovir
biosystem
inc
usa
use
vivo
experi
stock
viru
store
character
vivo
use
cotton
rat
model
replic
rsv
upper
lower
respiratori
tract
one
mous
vaccinationchalleng
experi
carri
sigmovir
biosystem
inc
usa
eighteen
balbc
mice
week
purchas
harlan
usa
maintain
handl
veterinari
supervis
anim
group
n
per
group
immun
prime
vaccin
day
booster
vaccin
day
second
booster
day
group
mock
vaccin
intranas
either
pb
group
mock
ml
per
dose
blpf
group
mg
flysgcn
bound
mg
blp
per
ml
dose
group
receiv
firsv
dilut
ml
per
dose
prepar
accord
calf
muscl
equal
divid
inject
site
fourteen
day
last
vaccin
anim
challeng
intranas
ml
rsv
suspens
plaqu
form
unit
pfu
rsvalong
per
anim
immun
challeng
perform
isofluran
anesthesia
blood
sampl
drawn
day
orbit
punctur
anim
sacrif
co
inhal
five
day
challeng
lung
remov
thorax
right
lung
inflat
formalin
histopatholog
see
lingular
lobe
left
lung
homogen
use
viru
titrat
see
one
cotton
rat
vaccinationchalleng
experi
carri
sigmovir
biosystem
inc
usa
fifteen
inbr
femal
sigmodon
hispidu
cotton
rat
week
age
sigmovir
biosystem
inc
rockvil
md
maintain
handl
veterinari
supervis
anim
group
n
per
group
immun
prime
vaccin
day
booster
vaccin
day
second
booster
day
group
mock
vaccin
intranas
either
pb
group
mock
ml
per
dose
blpf
mg
flysgcn
bound
mg
blp
per
ml
dose
group
receiv
firsv
dilut
ml
per
dose
prepar
accord
quadricep
equal
divid
inject
site
fourteen
day
last
vaccin
anim
challeng
intranas
ml
rsv
suspens
pfu
rsvalong
viru
per
anim
immun
challeng
perform
isofluran
anesthesia
blood
sampl
drawn
day
orbit
punctur
anim
sacrif
co
inhal
five
day
challeng
lung
remov
thorax
right
lung
inflat
formalin
histopatholog
see
lingular
lobe
left
lung
homogen
use
viru
titrat
see
antibodi
respons
rsv
f
determin
use
elisa
similarli
describ
previous
briefli
elisa
plate
high
bind
capac
greiner
coat
overnight
streptactinpurifi
fwt
fig
plate
block
block
buffer
mm
carbonatebicarbon
ph
protifarh
plu
ww
nutricia
netherland
subsequ
wash
determin
total
serum
igg
specif
titer
sampl
appli
plate
serial
triplefold
dilut
use
multichannel
pipett
mous
control
serum
sampl
posit
rsv
f
includ
plate
mous
igg
sigma
dilut
triplic
first
well
mgml
use
gener
calibr
curv
plate
incub
hr
follow
wash
step
plate
subsequ
incub
appropri
conjug
antimous
igg
conjug
hrp
southern
biotech
hr
hrp
activ
detect
similarli
describ
antif
igg
antibodi
level
serum
express
mgml
determin
use
calibr
curv
paramet
curv
determin
detect
siga
nose
lavag
similar
method
employ
use
undilut
wash
dilut
thereof
detect
antibodi
elisa
plate
incub
appropri
conjug
antimous
igahrp
conjug
southern
biotech
usa
titer
report
reciproc
calcul
sampl
dilut
correspond
od
least
background
correct
rsv
neutral
antibodi
titer
serum
sampl
determin
analyz
reduct
rsv
infect
presenc
serial
dilut
serum
sampl
two
differ
method
employ
first
heat
inactiv
serum
sampl
dilut
emem
serial
dilut
dilut
serum
sampl
incub
rsvalong
pfu
hour
room
temperatur
inocul
duplic
onto
confluent
monolay
plate
one
hour
incub
co
incub
cell
overlay
methylcellulos
medium
plate
incub
incub
four
day
later
overlay
remov
cell
fix
crystal
violet
stain
one
hour
rins
air
dri
correspond
reciproc
neutral
antibodi
titer
determin
reduct
endpoint
viru
control
use
statist
program
plqrdmanualentri
geometr
mean
standard
error
anim
group
given
time
calcul
altern
heat
inactiv
serum
sampl
mab
dilut
dmem
supplement
fetal
calf
serum
bodinco
b
v
uml
penicillin
mgml
streptomycin
serial
dilut
dilut
serum
sampl
incub
rsvalong
tissu
cultur
infecti
dose
hour
room
temperatur
inocul
duplic
onto
confluent
monolay
plate
hour
incub
co
incub
cell
fix
formaldehyd
solut
stain
palivizumab
goatantihuman
igg
conjug
jackson
immunoresearch
imag
cell
well
taken
use
evo
fluoresc
microscop
life
scienc
technolog
amount
infect
calcul
determin
total
area
infect
cell
use
imagej
neutral
titer
determin
reduct
point
viru
control
use
logarithm
equat
deriv
plot
dilut
versu
percentag
infect
lung
homogen
clarifi
centrifug
dilut
emem
confluent
monolay
infect
duplic
ml
per
well
start
undilut
neat
sampl
follow
dilut
homogen
plate
one
hour
incub
co
incub
inocula
remov
well
overlay
methylcellulos
medium
plate
restor
incub
day
incub
overlay
remov
cell
fix
crystal
violet
stain
one
hour
rins
air
dri
plaqu
count
viru
titer
express
pfu
per
gram
tissu
viral
titer
calcul
geometr
mean
plu
standard
error
anim
group
given
time
lung
dissect
inflat
neutral
buffer
formalin
normal
volum
immers
fix
solut
follow
fixat
lung
embed
paraffin
section
stain
hematoxylin
eosin
two
paramet
pulmonari
inflamm
evalu
interstiti
pneumonia
defin
inflammatori
cell
infiltr
thicken
alveolar
wall
alveol
defin
cell
within
alveolar
space
slide
score
blind
sever
scale
score
subsequ
convert
histopatholog
scale
immunogen
viral
load
analys
conduct
use
per
protocol
pp
popul
defin
subject
receiv
full
amount
treatment
blood
drawn
serolog
test
indic
day
mean
titer
mt
geometr
mean
titer
gmt
comput
compar
base
mannwhitney
u
test
differ
blpf
group
present
experi
assess
present
studi
aim
develop
rsv
vaccin
base
recombin
solubl
f
protein
ectodomain
bound
surfac
immunostimulatori
blp
previous
other
shown
express
fulli
cleav
solubl
f
protein
give
rise
multimer
form
either
postfus
conform
pretrigg
state
easili
adopt
postfus
conform
upon
exposur
lowmolar
buffer
similar
prepar
use
structur
determin
f
protein
also
observ
postfus
conform
howev
inhibit
furincleavag
f
appear
prevent
protein
adopt
postfus
conform
consist
cleavag
f
requir
activ
membran
fusion
other
previous
demonstr
recombin
solubl
class
fusion
protein
stabli
maintain
prefus
conform
ctermin
addit
artifici
trimer
domain
present
studi
appli
design
similar
previous
use
produc
recombin
solubl
bioactiv
influenza
viru
hemagglutinin
protein
express
solubl
rsv
f
protein
thu
human
codonoptim
rsv
f
ectodomain
sequenc
european
type
clinic
isol
preced
signal
peptideencod
sequenc
follow
sequenc
code
isoleucin
zipper
trimer
motif
appropri
tag
refer
fwtgcn
fig
comparison
f
protein
also
clone
vector
without
sequenc
encod
trimer
motif
refer
fwt
tag
consist
either
tripl
streptag
easi
purif
lysm
peptidoglycan
bind
domain
bind
f
protein
blp
combin
thereof
turn
yet
unknown
reason
f
construct
express
higher
level
also
lysm
domain
present
data
shown
addit
wildtyp
construct
fwt
fwtgcn
specifi
f
protein
nonmodifi
furin
cleavag
site
also
construct
express
vector
encod
f
protein
modifi
furincleavag
site
arginin
multibas
furin
cleavag
site
substitut
lysin
fli
flysgcn
express
f
protein
ectodomain
achiev
transient
transfect
express
plasmid
cell
f
protein
express
secret
cell
cultur
media
purifi
singl
step
protocol
use
streptactin
bead
analyz
sdspage
follow
western
blot
use
palivizumab
shown
fig
epitop
recogn
palivizumab
locat
part
f
protein
fig
f
ectodomain
subject
sdspage
reduc
condit
ie
presenc
result
separ
otherwis
disulfidelink
moieti
protein
migrat
differ
electrophoret
mobil
correspond
absenc
presenc
sequenc
fig
furthermor
f
protein
migrat
higher
posit
gel
furincleavag
site
mutat
compar
fwt
fli
fwtgcn
flysgcn
agreement
protein
cleav
f
protein
prepar
subject
sdspage
absenc
reduc
agent
migrat
noncleav
f
protein
appear
much
affect
fig
contrast
fwt
fwtgcn
protein
clearli
ran
lower
posit
gel
fli
flysgcn
protein
reduc
condit
differ
electrophorect
mobil
appear
much
smaller
absenc
reduc
agent
agreement
part
still
attach
part
via
disulfid
bridg
also
furincleav
protein
small
differ
electrophoret
mobil
cleav
noncleav
f
protein
still
notic
like
explain
dissoci
glycosyl
sequenc
cleav
protein
interestingli
electrophoret
mobil
cleav
f
protein
dramat
chang
prepar
heat
prior
electrophoresi
nonreduc
condit
contrast
noncleav
protein
fli
flysgcn
major
fwt
fwtgcn
protein
migrat
much
higher
posit
gel
absenc
heat
appear
higher
order
f
protein
structur
may
explain
cleav
f
protein
adopt
stabl
postfus
conform
character
presenc
extrem
stabl
resist
sd
unless
prepar
heat
interpret
agreement
previou
studi
show
larg
major
solubl
cleav
f
ectodomain
adopt
postfus
conform
strikingli
put
postfus
conform
prevent
ectodomain
extend
artifici
trimer
domain
stabl
postfus
form
f
form
howev
f
protein
cleav
confirm
extend
observ
subsequ
perform
experi
purifi
f
protein
subject
limit
proteolysi
follow
sdspage
nonreduc
condit
furincleavag
site
fli
flysgcn
mutat
substitut
arginin
lysin
posit
f
still
sensit
trypsin
digest
treatment
fli
flysgcn
protein
trypsin
thu
result
cleavag
protein
possibl
format
sdsresist
higherord
structur
presum
correspond
f
protein
postfus
conform
fig
fwt
fwtgcn
protein
includ
control
purifi
protein
detect
use
colloid
blue
stain
fwt
fwtgcn
ran
expect
posit
gel
sampl
heat
prior
electrophoresi
sampl
heat
protein
ran
much
higher
posit
gel
agreement
result
shown
fig
expect
treatment
sampl
trypsin
affect
migrat
higher
order
structur
much
higher
order
structur
fwtgcn
appear
somewhat
less
distinct
may
relat
trypsin
treatment
result
remov
f
protein
tag
extent
demonstr
appear
lower
migrat
f
protein
speci
sampl
heat
prior
electrophoresi
fig
western
blot
analysi
use
tagspecif
antibodi
data
shown
treatment
noncleav
f
protein
fli
flysgcn
trypsin
result
appear
f
protein
migrat
much
higher
posit
gel
nonreduc
condit
least
sampl
boil
prior
electrophoresi
similarli
fwt
fwtgcn
counterpart
format
sdsresist
higherord
structur
appar
fli
flysgcn
indic
format
put
postfus
conform
impair
extent
trimer
motif
next
probe
reactiv
f
protein
prepar
rsv
neutral
mab
palivizumab
use
elisa
format
palivizumab
recogn
f
protein
postfus
conform
also
appear
recogn
conform
state
would
explain
neutral
activ
mab
although
specif
rsv
f
previous
shown
display
littl
reactiv
cleav
solubl
f
protein
ectodomain
like
adopt
postfus
conform
agreement
herewith
antibodi
recent
identifi
prefusionspecif
shown
fig
palivizumab
display
concentrationdepend
bind
f
protein
prepar
consist
antibodi
recogn
f
protein
irrespect
conform
state
contrast
abl
bind
fwt
agreement
conclus
protein
adopt
postfus
conform
howev
intermedi
bind
observ
cleav
protein
extend
trimer
motif
fwtgcn
cleavag
prevent
fli
highest
reactiv
observ
two
featur
combin
flysgcn
trypsin
treatment
fli
flysgcn
prior
coat
well
result
reduc
reactiv
becom
compar
reactiv
observ
cleav
f
protein
fwt
fwtgcn
reactiv
palivizumab
f
protein
affect
trypsin
treatment
reactiv
differ
f
protein
prepar
similar
compar
abil
differ
mab
neutral
rsv
infect
cell
much
less
palivizumab
need
achiev
neutral
fig
conclus
result
indic
bind
palivizumab
differ
differ
f
protein
prepar
fwt
presum
adopt
postfus
conform
least
detect
highest
reactiv
observ
flysgcn
appar
flysgcn
display
one
addit
epitop
recogn
neutral
antibodi
f
protein
ectodomain
adopt
postfus
conform
importantli
recogn
addit
epitop
potent
inhibitor
rsv
infect
aim
develop
needlefre
mucos
vaccin
base
blp
technolog
next
assess
bind
lysm
domaincontain
f
protein
blp
end
cultur
media
cell
transfect
earlier
plasmid
encod
differ
lysmtag
f
ectodomain
incub
blp
blp
collect
centrifug
amount
f
protein
bound
blp
determin
compar
colloid
blue
stain
f
protein
sdspa
gel
rel
bsa
standard
fig
bind
detect
absenc
lysm
domain
data
shown
lysm
domainmedi
bind
f
blp
much
effici
presenc
trimer
domain
appar
trimer
domain
somehow
enhanc
bind
f
protein
carri
singl
lysm
domain
blp
bind
f
blp
also
visual
confoc
microscopi
use
palivizumab
fig
show
even
distribut
f
surfac
blp
final
analyz
blp
load
f
notic
contrast
blp
carri
flysgcn
blp
display
fwtgcn
aggreg
fig
result
agreement
fwtgcn
protein
unlik
flysgcnadopt
least
part
postfus
conform
wherebi
hydrophob
fusion
peptid
becom
expos
subsequ
result
aggreg
f
proteinbound
blp
flysgcn
display
extens
relev
epitop
repertoir
postfus
f
caus
blp
aggreg
upon
bind
contrast
blp
load
fwtgcn
perform
immun
experi
mice
blp
display
flysgcn
refer
blpf
first
studi
antibodi
respons
three
intranas
immun
blp
prepar
comparison
mice
also
immun
three
time
intranas
unadjuv
flysgcn
protein
intramuscularli
firsv
vaccin
anim
display
fspecif
igg
level
highest
level
fold
higher
observ
anim
vaccin
blpf
fig
antibodi
observ
immun
empti
blp
data
shown
character
phenotyp
immun
respons
found
mice
immun
blpf
display
higher
fspecif
level
anim
receiv
firsv
fig
unadjuv
flysgcn
protein
result
significantli
higher
ratio
fig
p
observ
indic
antibodi
respons
induc
intranas
applic
blpf
display
balanc
phenotyp
respons
induc
firsv
sever
expect
furthermor
fspecif
siga
titer
nose
observ
intranas
immun
blpf
firsv
unadjuv
flysgcn
protein
fig
indic
blpf
capabl
induc
mucos
immun
respons
respiratori
tract
next
determin
whether
blpf
abl
induc
protect
immun
rsv
infect
end
mice
vaccin
three
time
intranas
blpf
anim
mock
vaccin
pb
firsv
intramuscularli
includ
control
fourteen
day
last
vaccin
mice
challeng
inocul
rsvalong
pfu
serum
sampl
collect
day
show
vaccin
anim
except
one
receiv
pb
display
fspecif
igg
level
highest
level
observ
anim
vaccin
blpf
fig
signific
day
p
result
agreement
viru
neutral
titer
determin
pool
sera
collect
day
fig
viral
infect
titer
lung
determin
day
post
inocul
highest
titer
observ
mockvaccin
anim
receiv
pb
titer
detect
limit
observ
vaccin
blpf
fig
result
indic
blpf
given
intranas
capabl
induc
protect
immun
mice
moreov
pulmonari
histopatholog
examin
show
score
interstiti
pneumonia
alveol
mice
vaccin
blpf
wherea
expect
high
level
score
lung
anim
vaccin
firsv
fig
final
vaccin
challeng
experi
perform
use
cotton
rat
anim
model
rsv
model
particularli
suitabl
reproduc
symptom
vaccinationassoci
enhanc
diseas
observ
natur
infect
children
previous
vaccin
firsv
thu
cotton
rat
mock
vaccin
intranas
blpf
pb
vaccin
intramuscularli
firsv
except
mockvaccin
cotton
rat
vaccin
anim
display
high
igg
titer
day
post
vaccin
onward
titer
elicit
intranas
appli
blpf
highest
fig
anim
vaccin
blpf
day
post
vaccin
demonstr
detect
high
viru
neutral
titer
fig
viru
neutral
titer
plateau
first
boost
primeboost
vaccin
contribut
second
boost
observ
fourteen
day
last
vaccin
cotton
rat
challeng
rsvalong
pfu
day
post
challeng
anim
euthan
viral
titer
lung
determin
anim
vaccin
blpf
firsv
display
signific
reduct
lung
titer
respect
fig
agreement
observ
mice
pulmonari
histopatholog
examin
show
score
interstiti
pneumonia
alveol
cotton
rat
vaccin
blpf
wherea
expect
high
level
score
lung
anim
vaccin
firsv
fig
e
conclus
show
vaccin
mice
cotton
rat
blpf
result
protect
immun
associ
vaccinationrel
enhanc
diseas
symptom
global
rsv
common
caus
childhood
acut
lower
respiratori
infect
alri
major
caus
hospit
admiss
due
sever
alri
elderli
hospit
rate
rsv
similar
associ
influenza
despit
morbid
mortal
caus
rsv
licens
vaccin
rsv
avail
show
recombin
solubl
f
protein
mutat
furin
cleavag
site
ctermin
extend
trimer
motif
assum
prefusionlik
conform
rather
adopt
postfus
form
expos
extens
relev
epitop
repertoir
intranas
vaccin
mice
cotton
rat
blp
load
recombin
f
protein
blpf
induc
high
rsv
fspecif
igg
siga
level
viru
neutral
antibodi
titer
significantli
decreas
rsv
titer
lung
upon
rsv
challeng
contrast
vaccin
firsv
immun
blpf
induc
enhanc
respiratori
diseas
symptom
infect
high
dose
rsv
differ
recombin
solubl
f
protein
prepar
analyz
studi
solubl
cleav
f
protein
fwt
shown
adopt
higherord
structur
resist
sd
indic
format
stabl
display
high
reactiv
mab
palivizumab
recogn
preand
postfus
form
f
prefusionspecif
mab
collect
result
indic
solubl
cleav
f
protein
postfus
form
agreement
observ
made
sever
studi
similar
solubl
f
protein
construct
express
one
studi
major
solubl
cleav
f
protein
prefus
state
conform
stabl
protein
readili
adopt
postfus
state
exposur
low
molar
buffer
interestingli
addit
artifici
trimer
motif
carboxi
terminu
solubl
cleav
f
protein
fwtgcn
prevent
f
protein
adopt
postfus
conform
judg
format
sdsresist
heatsensit
higherord
structur
consist
blp
carri
fwtgcn
found
aggreg
attribut
hydrophob
interact
fusion
peptid
expos
postfus
conform
somewhat
increas
reactiv
fwtgcn
compar
fwt
probabl
explain
proport
protein
adopt
postfus
conform
actual
abil
major
fwtgcn
adopt
postfus
conform
remark
addit
trimer
motif
sever
class
fusion
protein
suffici
keep
protein
prefus
conform
heat
solubl
cleav
form
f
protein
parainfluenza
viru
piv
also
paramyxoviru
requir
protein
adopt
postfus
conform
heat
requir
rsv
f
counterpart
fwtgcn
studi
result
thu
indic
metast
prefus
conform
figur
bind
recombin
f
protein
blp
bind
efficaci
variou
f
protein
fwt
fwtgcn
fli
flysgcn
carri
ctermin
lysm
domain
tag
blp
determin
incub
equal
amount
mg
f
protein
mg
blp
use
standard
condit
amount
f
protein
bound
blp
determin
compar
sdspage
analysi
colloid
blue
stain
f
protein
compar
bsa
standard
b
analyz
bind
pattern
f
blp
blp
carri
flysgcn
lysm
domain
blpf
gener
use
standard
condit
follow
incub
palivizumab
fitclabel
goatantihuman
secondari
antibodi
control
empti
blp
use
prepar
analyz
use
bright
field
fluoresc
microscopi
c
blp
display
fwtgcn
flysgcn
analyz
use
bright
field
microscopi
rsv
f
protein
intrins
unstabl
class
fusion
protein
prevent
furincleavag
solubl
rsv
f
ectodomain
clearli
affect
conform
state
secret
protein
noncleav
solubl
f
protein
adopt
postfus
conform
judg
absenc
sdsresist
heat
sensit
higherord
structur
noncleav
f
protein
also
somewhat
better
recogn
mab
cleav
counterpart
trypsin
digest
cleavag
mutant
f
protein
result
sdsresist
heat
sensit
higher
order
structur
concomit
reduct
reactiv
bind
noncleav
f
protein
blp
result
aggreg
blp
indic
fusion
peptid
expos
result
agreement
observ
show
noncleav
rsv
f
adopt
anoth
conform
state
cleav
f
exemplifi
differ
f
protein
morpholog
observ
electron
microscopi
furthermor
noncleav
f
protein
form
rosett
result
hydrophob
interact
fusion
peptid
case
cleav
f
strikingli
howev
f
protein
two
paramyxovirus
shown
adopt
postfus
conform
even
absenc
f
protein
cleavag
although
noncleav
heat
f
protein
found
recogn
antibodi
specif
recogn
cleav
postfus
state
differ
f
protein
produc
studi
flysgcn
construct
came
attract
antigen
vaccin
flysgcn
noncleav
f
protein
carboxytermin
extend
trimer
motif
adopt
put
postfus
conform
display
highest
reactiv
prefusionspecif
mab
indic
protein
assum
prefusionlik
conform
research
need
elucid
whether
flysgcn
protein
adopt
nativ
prefus
state
rather
intermedi
conform
importantli
antibodi
much
higher
antirsv
neutral
capac
palivizumab
studi
antigen
mimic
prefusionlik
form
f
expos
least
one
addit
epitop
recogn
neutral
antibodi
compar
postfus
form
flysgcn
bound
blp
gener
blpf
vaccin
candid
direct
comparison
postfus
f
protein
prepar
pursu
unaccept
aggreg
observ
blp
display
fwtgcn
intranas
vaccin
mice
cotton
rat
blpf
result
induct
fspecif
igg
level
sera
siga
titer
nose
lavag
higher
observ
anim
vaccin
intramuscularli
firsv
intranas
unadjuv
f
protein
moreov
high
serum
level
viru
neutral
antibodi
observ
vaccin
blpf
cotton
rat
mice
result
confirm
known
adjuv
properti
blp
use
intranas
show
intranas
applic
blpf
result
rsv
fspecif
system
mucos
immun
respons
viru
neutral
antibodi
direct
rsv
f
protein
known
correl
protect
rsv
infect
demonstr
amongst
other
success
current
avail
immun
treatment
rsv
infect
palivizumab
prevent
seriou
rsv
ill
prematur
children
patient
bronchopulmonari
dysplasia
consist
high
level
viru
neutral
serum
antibodi
siga
titer
nose
lavag
elicit
studi
intranas
vaccin
blpf
result
protect
mice
cotton
rat
evidenc
significantli
reduc
viru
titer
lung
anim
whether
local
fspecif
siga
import
protect
rsv
infect
diseas
well
establish
passiv
nasal
transfer
mous
monoclon
iga
antibodi
rsv
f
glycoprotein
significantli
reduc
viral
shed
nose
throat
lung
rhesu
monkey
model
rsv
infect
suggest
role
local
siga
protect
whether
blpf
induc
local
siga
respons
contribut
protect
deduc
present
set
result
howev
previou
experi
intranas
administ
influenza
vaccin
mix
blp
result
superior
protect
homolog
heterolog
influenza
viru
infect
compar
convent
intramuscular
immun
even
though
hemagglutin
inhibit
titer
sera
deriv
anim
receiv
intranas
blp
vaccin
elev
compar
vaccin
anim
result
suggest
role
local
immun
protect
capac
intranas
blpbase
vaccin
clearli
interest
studi
whether
blpf
capabl
induc
similar
first
line
defens
rsv
infect
upper
andor
lower
respiratori
tract
mucosa
result
indic
vaccin
blpf
safe
use
mice
cotton
rat
sign
enhanc
respiratori
diseas
symptom
form
alveol
interstiti
pneumonia
observ
lung
blpf
vaccin
anim
subsequ
challeng
rsv
contrast
vaccin
firsv
follow
rsv
challeng
induc
sever
enhanc
diseas
symptom
expect
observ
exact
mechan
vaccin
firsv
induc
enhanc
respiratori
diseas
infant
infect
still
clear
recent
work
mice
implic
failur
firsv
induc
viru
neutral
antibodi
poor
affin
matur
like
caus
lack
suffici
tlr
stimul
well
excess
immun
respons
absenc
enhanc
diseas
symptom
vaccin
blpf
may
therefor
explain
blpf
driven
induct
robust
serum
level
viru
neutral
antibodi
accompani
rel
high
ratio
typic
better
balanc
type
immun
respons
compar
anim
receiv
firsv
although
phenotyp
immun
respons
induc
nasal
administr
blpf
need
explor
type
follow
challeng
rsvalong
pfu
day
last
vaccin
fspecif
igg
titer
immun
day
week
immun
day
b
rsv
neutral
titer
three
immun
serum
pool
anim
group
day
c
viru
titer
lung
day
challeng
limit
detect
pfugr
day
post
challeng
lung
harvest
pulmonari
histopatholog
examin
interstiti
pneumonia
alveol
score
describ
materi
method
standard
error
mean
sem
indic
error
bar
group
receiv
blpf
compar
group
day
use
mannwhitney
u
test
p
respons
agreement
previou
studi
use
blpbase
vaccin
exampl
intranas
immun
blp
mix
influenza
subunit
vaccin
elicit
skew
immun
respons
compar
induc
intramuscular
intranas
administ
influenza
subunit
vaccin
alon
respect
tlr
stimul
mediat
affinitymatur
noteworthi
blp
act
agonist
drive
matur
human
dendrit
cell
macrophag
vitro
role
blp
depend
immun
stimul
recent
confirm
vivo
experi
use
mice
unpublish
data
conclus
shown
least
one
epitop
recogn
neutral
antibodi
present
rsv
f
protein
adopt
postfus
conform
preserv
recombin
solubl
rsv
f
protein
mutat
furincleavag
site
combin
addit
ctermin
trimer
motif
intranas
vaccin
mice
cotton
rat
blpbase
vaccin
carri
prefusionlik
f
protein
shown
result
high
level
fspecif
igg
sera
local
siga
nose
viru
neutral
antibodi
mice
cotton
rat
vaccin
blpf
show
reduc
viru
titer
lung
challeng
absenc
enhanc
diseas
symptom
contrast
anim
receiv
firsv
figur
sequenc
trimer
domain
tag
use
carboxytermin
residu
rsv
f
protein
ectodomain
shown
blue
tripl
streptagii
ital
green
trimer
domain
red
bold
lysm
domain
underlin
includ
lysm
linker
sequenc
indic
f
protein
contain
use
vitro
analysi
lysm
domaincontain
protein
lack
tag
use
blp
bind
docx
